Citation Impact
Citing Papers
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2016 Standout
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer
2015
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
2013
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
2012
Is Transport Infrastructure Effective?: Transport Infrastructure and Accessibility: Impacts on the Space Economy
1998
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
2016
MET is required for the recruitment of anti-tumoural neutrophils
2015 Nature
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression
2019 Standout
Rapidly progressing mycosis fungoides presenting as follicular mucinosis
2000
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006
2010 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Follicular mucinosis: Clinical and histopathologic study
1989
Gastric cancer—molecular and clinical dimensions
2013
Prevalence of skin diseases in rural areas of Assiut Governorate, Upper Egypt
2003
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Syringotropic cutaneous T-cell lymphoma: a variant of mycosis fungoides?
1994
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
The Epidemiology of Skin Cancer
1996 Standout
Colorectal cancer
2019 Standout
Treating ALK-positive lung cancer—early successes and future challenges
2012
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
2012 Standout
Folliculotropic mycosis fungoides with large‐cell transformation presenting as dissecting cellulitis of the scalp
1997
BRAF inhibition improves tumor recognition by the immune system
2012
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
The emerging role of MET/HGF inhibitors in oncology
2013
Case 21-2013
2013
Role of PD-1 in Immunity and Diseases
2017 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
2014
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies
2018
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
2017
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin
1991
Neutrophils in cancer: neutral no more
2016 Standout
Increasing Incidence of Lentigo Maligna Melanoma Subtypes: Northern California and National Trends 1990–2000
2005
Which drug, and when, for patients with BRAF-mutant melanoma?
2013
Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
2014
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
2014
Solar (actinic) keratosis is squamous cell carcinoma
2006
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
2016
Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012
2015 Standout
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Accessibility evaluation of land-use and transport strategies: review and research directions
2003 Standout
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
1997 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
Cancer treatment and survivorship statistics, 2016
2016 Standout
Follicular mycosis fungoides
1993
Update on Metastatic Gastric and Esophageal Cancers
2015
Metabolic reprogramming and cancer progression
2020 StandoutScience
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
2013
Natural product and natural product derived drugs in clinical trials
2014 Standout
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma
2015
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
2008 Standout
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects
2014
Immune Checkpoint Inhibitors in Melanoma
2015
Cancer treatment and survivorship statistics, 2014
2014 Standout
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
2007 Standout
Works of A. B. Ackerman being referenced
What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer
1988
Large-Cell Acanthoma Is a Solar Lentigo
1992
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
2014
Vemurafenib-Induced Cardiac Tamponade: A Rare But Potentially Life-Threatening Complication
2013
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
2011
Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.
2012
Follicular mucinosis. A reaction pattern in follicular epithelium.
1985
Ideas in pathology. Malignant melanoma in situ: the evolution of a concept.
1990